CRSP — Crispr Therapeutics AG Share News
0.000.00%
Last trade - 00:00- $4.98bn
- $3.20bn
- $3.51m
CRISPR gains as FDA panel completes review of gene therapy
Press Digest: New York Times business news - Nov 1
FDA panel says Vertex/CRISPR to assess safety risks of gene therapy in follow-up study
US FDA advisers to consider need for more studies for Vertex/CRISPR gene therapy (updated)
US FDA staff says safety risks not clear for Vertex/CRISPR's gene therapy
Editas Medicine rises as Citi upgrades to 'buy'
Brief: CRISPR Therapeutics Proposes To Elect Sandy Mahatme To Its Board Of Directors
Brief: CRISPR Therapeutics Announces Leadership Transition
founder Rodger Novak to step down as chairman; shares fall
U.S. watchdog lifts price estimate for Bluebird, Vertex/CRISPR gene therapies to $2.1 mln (updated)
U.S. watchdog lifts price estimate for Bluebird, Vertex/CRISPR gene therapies to $2.1 mln
Brief: Crispr Therapeutics says FDA Accepted Biologics License Application For Exa-Cel
CRISPR rises after FDA accepts review of first ever gene editing therapy
Brief: Crispr Therapeutics Reports First Quarter 2023 Financial Results
Bluebird, CRISPR rise as pricing group reviews sickle-cell disease therapies
Bluebird, CRISPR gain as pricing group reviews sickle-cell disease therapies
Vertex/CRISPR's gene editing therapy cost effective at $1.9 million - pricing review group (updated)
Vertex/CRISPR's gene editing therapy cost effective at $1.9 million - pricing review group
CRISPR Therapeutics rises on getting $100 mln upfront in Vertex licensing pact